🔎 Trials Near Me

Beranda › Mieloma Multipel › Utah

Uji klinis Mieloma Multipel di Utah

21 studi untuk Mieloma Multipel mencari peserta di lokasi di Utah.

Kota di Utah

Teks studi resmi (Bahasa Inggris)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Salt Lake City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07391657

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • Huntsman Cancer Institute, Salt Lake City
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Utah Cancer Specialists, Salt Lake City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07518186

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Huntsman Cancer Institute, Salt Lake City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  • Utah Cancer Specialists, Salt Lake City
  • Huntsman Cancer Institute, Salt Lake City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  • LDS Hospital, Salt Lake City
  • Intermountain Cancer Center St. George, St. George
  • St. George Regional Hospital, St. George
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05623020

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center, Cedar City
  • Intermountain Healthcare, Salt Lake City
  • Dixie Regional Medical Center-River Road Campus, St. George
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • Huntsman Cancer Institute, Salt Lake City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • LDS Hospital, Salt Lake City
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  • Huntsman Cancer Institute /ID# 271618, Salt Lake City
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06953960

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06517017

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

  • Huntsman Cancer Institute, Salt Lake City
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05344833

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Salt Lake City
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05850234

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07280013

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  • Huntsman Cancer Institute /ID# 272575, Salt Lake City
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT06892522

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2026 · NCT05405387

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

  • Huntsman Cancer Center Institute University of Utah, Salt Lake City
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06433947

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of Utah, Salt Lake City
Menerima pesertaFase 1
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT04988555

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT06357754

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT05722418

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.